Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

NCT00526045 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Hematologic Neoplasms

Interventions

DRUG: AUY922 2 mg/m2

Sponsor

Novartis Pharmaceuticals